Moreover, genetically reducing Nrp1 levels enhances the severity of CMT2D pathology, whereas providing additional VEGF-A165, via lentiviral intramuscular injections, improves the phenotype10. This evidence concerns the gene NRP1 and Autosomal dominant Charcot-Marie-Tooth disease type 2D.